BCL2L1 and Thrombocytopenia: DT2216 is a PROTAC that targets BCL-XL to the Von Hippel-Lindau (VHL) E3-ligase, and, because there is limited expression in platelets, it has been shown to reduce on-target thrombocytopenia in mouse models, with a first-in-human study ongoing [148,149].